Doha, Qatar: Hamad Medical Corporation (HMG) has unveiled two groundbreaking treatment options for patients struggling with treatment-resistant depression at its Mental Health Service located in Mesaieed General Hospital: Esketamine and Transcranial Magnetic Stimulation (TMS).

"The introduction of Esketamine marks a crucial

advancement in our approach to treating depression. This nasal spray offers hope to patients who have struggled with traditional treatments, providing them with a new avenue for recovery,” said Dr. Ovais Wadoo FRCP(Edin), FRCPsych, Senior Consultant and Clinical Lead for Neuromodulation Services at HMC.

Esketamine is approved by the FDA and is administered in a clinical environment under the careful supervision of healthcare professionals. This treatment is especially advantageous for those who have not had success with antidepressants.

Alongside Esketamine, HMC will soon provide TMS therapy, which employs magnetic pulses to target specific brain areas linked to mood regulation. Dr. Ovais shares, "TMS is a non-invasive option for those who cannot handle the side effects of conventional medications or have not experienced their benefits. We are excited to offer this service to our patients."